



4 September 2008

Perth, Western Australia

## **PHYLOGICA PARTNERS WITH LEADING UK RESEARCHERS TO DEVELOP NEW CANCER DRUGS**

- **Phylogica technology to be used by Cambridge University and UK Medical Research Council initiative for drug discovery purposes**
- **Phylogica libraries to be developed into new format, which expands the ways to find new drugs and drug targets**
- **Facilitates the development of new cancer drugs**

Australian drug discovery company Phylogica (**ASX: PYC**) today announced it had signed a joint agreement with world-class researchers from the Medical Research Council and Cambridge University's Cambridge Molecular Therapeutics Programme (CMTP) to facilitate the development and commercialisation of novel cancer drugs.

The first stage of the collaboration will see the translation of Phylogica's exclusive Phylomer® peptide library into a new format, increasing the ways these libraries can be screened to identify potential drug candidates.

This program will be headed by Professor Ashok Venkitaraman and Dr Grahame McKenzie, working with other leading scientists in the Cambridge Molecular Therapeutics Programme and the MRC Cancer Cell Unit at the Hutchison/MRC Research Centre in Cambridge.

Professor Venkitaraman said the Phylomer® libraries are a unique asset.

"The Phylogica libraries contain more than 260 million Phylomer® peptides and we are very excited at the prospect of applying this novel technology in cancer," Professor Venkitaraman said.

Phylogica's Executive Chairman, Mr Aki von Roy, said the collaboration highlights international interest in Phylogica's Phylomer® technology and adds significant value to the technology for potential partners.

"This collaboration allows Phylogica to demonstrate the broad and multiple application of its exclusive Phylomer® technology while maintaining internal focus on its own research projects," Mr von Roy said.

"The expansion into cancer through a world-leading collaborator opens up an even bigger potential market, highlighting the enormous breadth of application of the Phylomer® technology for diseases other than the anti-inflammatory field".

For personal use only

For further information, please contact:

<b>Phylogica</b> <b>Mr Harry Karelis</b> Deputy Chairman +61 413 056 328 <a href="mailto:hkarelis@titanbioventures.com">hkarelis@titanbioventures.com</a>	<b>Mr Aki von Roy</b> Executive Chairman +64 21556659 <a href="mailto:Aki.vonroy@biopacificventures.com">Aki.vonroy@biopacificventures.com</a>
---	---

**About:**

**Phylogica Ltd** (ASX: PYC) ([www.phylogica.com](http://www.phylogica.com)) is a biotechnology company involved in drug discovery, using its proprietary Phylomer<sup>®</sup> peptide libraries. Phylomer<sup>®</sup> peptides are stable fragments of naturally-occurring proteins which bind tightly and specifically to disease targets. Phylomer<sup>®</sup> peptides have drug-like properties, including specificity, potency, stability and flexible production, allowing for chemical or recombinant means of manufacturing. In addition, these unique peptides are able to block both extracellular and intracellular disease targets. Phylogica's proprietary Phylomer<sup>®</sup> libraries are collections of hundreds of millions of Phylomer<sup>®</sup> peptides that represent a rich source of drug leads for a broad range of disease targets.

**Cambridge Molecular Therapeutics Programme** ([www.cmt.cam.ac.uk](http://www.cmt.cam.ac.uk)) is a new Medical Research Council and University of Cambridge initiative that aims to accelerate progress in drug discovery by using a range of novel approaches. The CMTP harnesses a multi-disciplinary approach, involving leading Cambridge research teams in the fields of structural biology, chemistry, physics, and molecular cell biology, in order to develop therapeutic small molecules in the areas of cancer and infectious diseases. The CMTP is based within the Hutchison/MRC Research Centre ([www.hutchison-mrc.cam.ac.uk](http://www.hutchison-mrc.cam.ac.uk)) together with the MRC Cancer Cell Unit and programmes of the University of Cambridge Department Of Oncology. The CMTP is jointly directed by Professor Ashok Venkitaraman (MRC Cancer Cell Unit and Cambridge University Department of Oncology) and Professor Tom Blundell (Cambridge University Department of Biochemistry).

For personal use only